Publication:
Issues related to recent dengue vaccine development

dc.contributor.authorEiji Konishien_US
dc.contributor.otherKobe University School of Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-05-03T08:21:06Z
dc.date.available2018-05-03T08:21:06Z
dc.date.issued2011-12-01en_US
dc.description.abstractDengue fever (DF) and dengue heemorrhagic fever (DHF) are mosquito-transmitted diseases of global importance. Despite significant research efforts, no approved vaccines or antiviral drugs against these diseases are currently available. This brief article reviews the status of dengue vaccine development, with particular emphasis on the vaccine strategies in more advanced stages of evaluation; these include traditional attenuation, chimerization and engineered attenuation. Several aspects of these vaccine design strategies, including concerns about vaccine candidates inducing infection-enhancing antibodies, are also presented. © 2011 by The Japanese Society of Tropical Medicine.en_US
dc.identifier.citationTropical Medicine and Health. Vol.39, No.4 SUPPL. (2011), 63-71en_US
dc.identifier.doi10.2149/tmh.2011-S01en_US
dc.identifier.issn13494147en_US
dc.identifier.issn13488945en_US
dc.identifier.other2-s2.0-84863826505en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12164
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863826505&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleIssues related to recent dengue vaccine developmenten_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863826505&origin=inwarden_US

Files

Collections